Top Markets
#1 Black Phoenix Black Phoenix +735.12%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.73%
#3 THORChain THORChain +24.59%
#4 THORChain Yield THORChain Yield +18.33%
#5 TENDIES TENDIES +17.08%
#6 MiL.k Alliance MiL.k Alliance +15.92%
#7 Biconomy Biconomy +15.76%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +14.58%
#9 Bless Bless +14.30%
#10 XPIN Network XPIN Network +13.95%
Coin of the day
Black Phoenix Black Phoenix
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Hybio Pharmaceutical Co., Ltd. Hybio Pharmaceutical Co., Ltd.

Hybio Pharmaceutical Co., Ltd.

300199
Peringkat dalam Saham #5173
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Harga Saham
$3.33
Kapitalisasi Pasar
$2.95B
Perubahan (1 hari)
1.50%
Perubahan (1 tahun)
-8.64%
Negara
CN
Perdagangan Hybio Pharmaceutical Co., Ltd. (300199)

Kategori

Healthcare
Riwayat dividen untuk Hybio Pharmaceutical Co., Ltd. (300199)
Saham Hybio Pharmaceutical Co., Ltd. (simbol: 300199) telah membayar total 0 dividen.
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Pembayaran dividen untuk Hybio Pharmaceutical Co., Ltd. (300199) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (disesuaikan dengan stock split) Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Daftar semua pembayaran dividen
Tahun Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pembayaran dividen untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pembayaran dividen Negara
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
0.00%
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
0.00%
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
0.00%
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
0.00%
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
38.00%
IN